GlassScriptPhysician profile
Pervez Mussarat
NPI 1134121999
$2,772.93
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $894 · 2021: $1,050 · 2022: $176.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $532.64 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $350.81 | 2019-2021 | |
| Biogen, INC. | $322.37 | 2019-2021 | |
| Eisai INC. | $184.07 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $140.49 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $140.23 | 2021 | |
| Sk Life Science, INC. | $138.49 | 2020-2021 | |
| Lilly USA, LLC | $130.64 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $128.82 | 2019 | |
| Medtronic, INC. | $102.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $79.99 | 2021 | |
| Jazz Pharmaceuticals INC. | $56.25 | 2020-2021 | |
| Abbvie INC. | $52.92 | 2021 | |
| Genzyme Corporation | $44.64 | 2019 | |
| Horizon Therapeutics Plc | $43.25 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $42.62 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.33 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $38.08 | 2020-2021 | |
| Csl Behring | $37.05 | 2019-2020 | |
| Lundbeck LLC | $35.48 | 2019-2020 | |
| Strongbridge US INC. | $32.21 | 2020 | |
| Medtronic Vascular, INC. | $17.17 | 2019 | |
| Celgene Corporation | $15.24 | 2021 | |
| Emd Serono, INC. | $14.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.64 | 2021 | |
| Indivior INC. | $13.84 | 2020 | |
| Amgen INC. | $12.92 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.07 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pervez Mussarat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.